Cline Scientific AB Series B
Cline Scientific AB (publ), a life science company, develops cancer diagnostics and stem cell therapies in Sweden. The company's clinical-stage projects include StemCART, a stem cell therapy for joint repair; and CellRACE, a cancer diagnostic to predict metastasis. It also develops nanotechnology based products for work within Life Sciences. The company has collaboration with Sahlgrenska that dev… Read more
Cline Scientific AB Series B (CLINE-B) - Total Liabilities
Latest total liabilities as of December 2023: Skr2.62 Million SEK
Based on the latest financial reports, Cline Scientific AB Series B (CLINE-B) has total liabilities worth Skr2.62 Million SEK as of December 2023.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Cline Scientific AB Series B - Total Liabilities Trend (2012–2023)
This chart illustrates how Cline Scientific AB Series B's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Cline Scientific AB Series B Competitors by Total Liabilities
The table below lists competitors of Cline Scientific AB Series B ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
MURATA MFG
MU:MUR1
|
Germany | €422.49 Billion |
|
Elcora Advanced Materials Corp
PINK:ECORF
|
USA | $5.01 Million |
|
WORLD FUEL SERVICES
BE:WFK
|
Germany | €4.93 Billion |
|
Stifel Financial Corporation 5.20% Senior Notes due 2047
NYSE:SFB
|
USA | $32.98 Billion |
Liability Composition Analysis (2012–2023)
This chart breaks down Cline Scientific AB Series B's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.91 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.13 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.12 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Cline Scientific AB Series B's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Cline Scientific AB Series B (2012–2023)
The table below shows the annual total liabilities of Cline Scientific AB Series B from 2012 to 2023.
| Year | Total Liabilities | Change |
|---|---|---|
| 2023-12-31 | Skr2.62 Million | +93.06% |
| 2022-12-31 | Skr1.36 Million | -14.26% |
| 2021-12-31 | Skr1.58 Million | +58.09% |
| 2020-12-31 | Skr1.00 Million | -85.64% |
| 2019-12-31 | Skr6.97 Million | +499.06% |
| 2018-12-31 | Skr1.16 Million | -74.82% |
| 2017-12-31 | Skr4.62 Million | +307.87% |
| 2016-12-31 | Skr1.13 Million | +7.78% |
| 2015-12-31 | Skr1.05 Million | -21.60% |
| 2013-12-31 | Skr1.34 Million | -6.80% |
| 2012-12-31 | Skr1.44 Million | -- |